查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879194

腫瘤藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、給藥途徑、配銷通路、地區和競爭格局分類，2020-2030年預測

Oncology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球腫瘤藥物市場規模為2,286.5億美元，預計2030年將以13.33%的複合年成長率成長至4,845.4億美元。腫瘤藥物是用於預防、診斷和治療癌症的藥物，涵蓋多種治療方式，包括化療、標靶治療和免疫療法。市場成長的主要促進因素包括全球癌症發生率的上升、人口老化以及生物技術研發的不斷進步，這些因素推動了新型療法的發現。

市場概覽
預測期 2026-2030
2024年市場規模 2286.5億美元
2030年市場規模 4845.4億美元
2025-2030年複合年成長率 13.33%
成長最快的細分市場 標靶藥物
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球腫瘤藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（細胞毒性藥物、標靶藥物、荷爾蒙藥物、其他）
    • 依給藥途徑（口服、注射、其他）
    • 按配銷通路（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美腫瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腫瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太腫瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腫瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腫瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球腫瘤藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Johnson & Johnson

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 4689

The Global Oncology Drugs Market, valued at USD 228.65 Billion in 2024, is projected to experience a CAGR of 13.33% to reach USD 484.54 Billion by 2030. Oncology drugs are pharmaceutical agents developed for the prevention, diagnosis, and treatment of cancer, encompassing a diverse range of therapeutic modalities including chemotherapy, targeted therapies, and immunotherapies. The market's growth is primarily supported by the increasing global incidence of cancer, the demographic shift towards an aging population, and continuous advancements in biotechnological research and development driving the discovery of novel treatments.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 228.65 Billion
Market Size 2030USD 484.54 Billion
CAGR 2025-203013.33%
Fastest Growing SegmentTargeted Drugs
Largest MarketNorth America

Key Market Drivers

The global oncology drugs market is significantly influenced by the increasing global cancer incidence. The rising prevalence of cancer worldwide, fueled by aging populations, lifestyle changes, and environmental factors, creates a substantial and continuously growing patient pool requiring advanced therapeutic interventions. This demographic shift directly translates into heightened demand for effective cancer treatments, necessitating a broader portfolio of pharmaceutical solutions. According to the World Health Organization and the International Agency for Research on Cancer, in their February 2024 report, an estimated 20 million new cancer cases occurred globally in 2022, underscoring the urgent and expanding need for oncology drugs.

Key Market Challenges

The extensive expenditure associated with oncology drug development and stringent regulatory approval processes presents a significant impediment to the growth of the Global Oncology Drugs Market. The substantial financial investment required for research, preclinical studies, and multiple phases of clinical trials, coupled with the high failure rate of experimental therapies, makes the development pathway costly and uncertain. This financial burden restricts the number of new treatments that can be brought to market, as companies must carefully prioritize projects with the highest likelihood of success and return on investment.

Key Market Trends

The rising integration of artificial intelligence in drug development profoundly reshapes the global oncology market by accelerating the discovery and development of novel therapies. AI algorithms streamline target identification, optimize lead compounds, and predict clinical outcomes, significantly reducing the timelines and costs associated with bringing new cancer treatments to market. This technological shift enhances research and development productivity. In April 2025, Tempus AI, Inc. announced strategic collaborations with AstraZeneca and Pathos AI, Inc. to build a multimodal foundation model in oncology, involving $200 million in data licensing and model development fees, highlighting investment in AI driven therapeutic advancements. According to the Pistoia Alliance's 2024 Lab of the Future report, AI was a top investment area for 62 percent of respondents over the next two years.

Key Market Players

  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Johnson & Johnson

Report Scope:

In this report, the Global Oncology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Drugs Market, By Drug Class:

  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others

Oncology Drugs Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Oncology Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Oncology Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oncology Drugs Market.

Available Customizations:

Global Oncology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)
    • 5.2.2. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Oncology Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oncology Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Oncology Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Oncology Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Oncology Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oncology Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Oncology Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Oncology Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Oncology Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Oncology Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oncology Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oncology Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Oncology Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Oncology Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Oncology Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Oncology Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Oncology Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oncology Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Oncology Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Oncology Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Oncology Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oncology Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Oncology Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Oncology Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oncology Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Astellas Pharma Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer, Inc.
  • 15.3. Novartis AG
  • 15.4. Astrazeneca Plc
  • 15.5. Merck & Co., Inc.
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. Amgen, Inc.
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Abbvie Inc.
  • 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer